18-[[1-Carboxy-4-oxo-4-[2-[2-[2-oxo-2-[2-[2-(2-oxoethoxy)ethoxy]ethylamino]ethoxy]ethoxy]ethylamino]butyl]amino]-18-oxooctadecanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 18-[[1-Carboxy-4-oxo-4-[2-[2-[2-oxo-2-[2-[2-(2-oxoethoxy)ethoxy]ethylamino]ethoxy]ethoxy]ethylamino]butyl]amino]-18-oxooctadecanoic acid
• 英文别名: 18-[[1-carboxy-4-oxo-4-[2-[2-[2-oxo-2-[2-[2-(2-oxoethoxy)ethoxy]ethylamino]ethoxy]ethoxy]ethylamino]butyl]amino]-18-oxooctadecanoic acid
• 化学式: C₃₅H₆₃N₃O₁₂
• 分子量: 717.9
• InChiKey: AJSAGMJPNUAXMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  50
• 可旋转键数：
  38
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  216
• 氢给体数：
  5
• 氢受体数：
  12

文献信息

• Polypeptide conjugates and methods of uses
  申请人：BEIJING QL BIOPHARMACEUTICAL CO., LTD.

  公开号：US11529394B2

  公开（公告）日：2022-12-20

  The present disclosure provides a polypeptide conjugates comprising GLP-1 receptor agonist and a peptide linker, and pharmaceutical compositions comprising the same. Methods of using such for treating diseases are also provided.

  本公开提供了一种由 GLP-1 受体激动剂和肽连接体组成的多肽共轭物，以及由其组成的药物组合物。还提供了用其治疗疾病的方法。
• CONJUGATES OF FUSION PROTEINS OF GLP-1 AND FGF21
  申请人：BEIJING QL BIOPHARMACEUTICAL CO., LTD.

  公开号：US20220016254A1

  公开（公告）日：2022-01-20

  The present disclosure provides conjugates of polypeptides comprising GLP-1, polypeptide linker and FGF21. Pharmaceutical compositions comprising the same and methods of treating diseases are also provided.
• POLYPEPTIDE CONJUGATES AND METHODS OF USES
  申请人：BEIJING QL BIOPHARMACEUTICAL CO., LTD.

  公开号：US20220133856A1

  公开（公告）日：2022-05-05

  The present disclosure provides a polypeptide conjugates comprising GLP-1 receptor agonist and a peptide linker, and pharmaceutical compositions comprising the same. Methods of using such for treating diseases are also provided.
• [EN] PROCESS FOR PRODUCING A TABLET COMPRISING GLP-1 PEPTIDES<br/>[FR] PROCÉDÉ DE PRODUCTION D'UN COMPRIMÉ COMPRENANT DES PEPTIDES GLP-1
  申请人：NOVO NORDISK AS

  公开号：WO2021043803A1

  公开（公告）日：2021-03-11

  The present invention relates to a process for producing a tablet comprising a GLP-1 peptide wherein the GLP-1 peptide is obtained by spray-drying of a feed solution comprising the GLP-1 peptide and a feed solution solvent, wherein the pH of the feed solution is higher that the pI of the GLP-1 peptide or wherein the pH of the feed solution is in the range of about 5 to about 10. The invention also relates to the tablet obtained by said process and the use of said tablet in medicine.